Relapses of Plasmodium vivax malaria are prevented by 8-aminoquinolines. If hypnozoites
survive, then the subsequent blood stage infections in early relapses (< 2 months) are …

There has been progress towards decreasing malaria prevalence globally; however,
Plasmodiumávivax has been less responsive to elimination efforts compared with …

Tafenoquine is a newly licensed antimalarial drug for the radical cure of Plasmodium vivax
malaria. The mechanism of action and optimal dosing are uncertain. We pooled individual …

Background WHO recommends gametocytocidal, single low-dose primaquine for blocking
the transmission of Plasmodium falciparum; however, safety concerns have hampered the …

Background There are no pharmacokinetic data of single low dose primaquine (SLDPQ) as
transmission blocking in African children with acute Plasmodium falciparum and glucose-6 …

There is a pressing need for compounds with broad-spectrum activity against malaria
parasites at various life cycle stages to achieve malaria elimination. However, this goal …

The scientific community worldwide has realized that malaria elimination will not be possible
without development of safe and effective transmission-blocking interventions. Primaquine …

Background Vector control interventions in sub-Saharan Africa rely on insecticide-treated
nets and indoor residual spraying. Insecticide resistance, poor coverage of interventions …

Background Artemisinin-based combination therapy (ACT) is recommended for
uncomplicated Plasmodium vivax malaria in areas of emerging chloroquine resistance. We …

Background Plasmodium vivax malaria requires a 2-week course of primaquine (PQ) for
radical cure. Evidence suggests that the hepatic isoenzyme cytochrome P450 2D6 …